These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27173586)

  • 1. Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies.
    Apovian C; Palmer K; Fain R; Perdomo C; Rubino D
    Diabetes Obes Metab; 2016 Sep; 18(9):945-8. PubMed ID: 27173586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability review of lorcaserin in clinical trials.
    Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
    Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.
    Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S
    Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders.
    Pi-Sunyer X; Shanahan W; Fain R; Ma T; Garvey WT
    Postgrad Med; 2016 Aug; 128(6):591-7. PubMed ID: 27389084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia.
    Nesto R; Fain R; Li Y; Shanahan W
    Postgrad Med; 2016 May; 128(4):364-70. PubMed ID: 27116910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT; Zhou S; Shanahan W; Fain R
    Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
    Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
    Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
    O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
    Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
    Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of lorcaserin in the management of obesity.
    Hess R; Cross LB
    Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
    Hurren KM; Berlie HD
    Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
    Nigro SC; Luon D; Baker WL
    Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Bohula EA; Scirica BM; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Kanevsky E; Murphy SA; Leiter LA; Dwyer JP; Corbalan R; Hamm C; Kaplan L; Nicolau JC; Ophuis TO; Ray KK; Ruda M; Spinar J; Patel T; Miao W; Perdomo C; Francis B; Dhadda S; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
    Lancet; 2018 Nov; 392(10161):2269-2279. PubMed ID: 30293771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: the look AHEAD study.
    Pownall HJ; Bray GA; Wagenknecht LE; Walkup MP; Heshka S; Hubbard VS; Hill J; Kahn SE; Nathan DM; Schwartz AV; Johnson KC;
    Obesity (Silver Spring); 2015 Mar; 23(3):565-72. PubMed ID: 25707379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss.
    Handelsman Y; Fain R; Wang Z; Li X; Fujioka K; Shanahan W
    Postgrad Med; 2016 Nov; 128(8):740-746. PubMed ID: 27659698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
    Martin CK; Redman LM; Zhang J; Sanchez M; Anderson CM; Smith SR; Ravussin E
    J Clin Endocrinol Metab; 2011 Mar; 96(3):837-45. PubMed ID: 21190985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
    Scirica BM; Bohula EA; Dwyer JP; Qamar A; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Murphy SA; Im K; Leiter LA; Gupta M; Patel T; Miao W; Perdomo C; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
    Circulation; 2019 Jan; 139(3):366-375. PubMed ID: 30586726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
    Bohula EA; Wiviott SD; McGuire DK; Inzucchi SE; Kuder J; Im K; Fanola CL; Qamar A; Brown C; Budaj A; Garcia-Castillo A; Gupta M; Leiter LA; Weissman NJ; White HD; Patel T; Francis B; Miao W; Perdomo C; Dhadda S; Bonaca MP; Ruff CT; Keech AC; Smith SR; Sabatine MS; Scirica BM;
    N Engl J Med; 2018 Sep; 379(12):1107-1117. PubMed ID: 30145941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?
    Kolotkin RL; Crosby RD; Wang Z
    Clin Obes; 2017 Dec; 7(6):347-353. PubMed ID: 28815987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.